MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Codexis Inc

Closed

SectorHealthcare

2.5 -3.85

Overview

Share price change

24h

Current

Min

2.45

Max

2.6

Key metrics

By Trading Economics

Income

7.4M

-13M

Sales

7.8M

15M

EPS

-0.16

Profit margin

-86.587

Employees

188

EBITDA

7.6M

-13M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+144.4% upside

Dividends

By Dow Jones

Next Earnings

30 Oct 2025

Market Stats

By TradingEconomics

Market Cap

11M

243M

Previous open

6.35

Previous close

2.5

News Sentiment

By Acuity

37%

63%

128 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Codexis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 Oct 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 Oct 2025, 17:03 UTC

Major Market Movers

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 Oct 2025, 23:53 UTC

Market Talk

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 Oct 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 Oct 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 21:36 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 Oct 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 Oct 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 Oct 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

13 Oct 2025, 20:35 UTC

Acquisitions, Mergers, Takeovers

Goldman Expects to Close Deal in 1Q

13 Oct 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 Oct 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 Oct 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 Oct 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 Oct 2025, 20:29 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Buy VC Firm Industry Ventures

13 Oct 2025, 19:05 UTC

Market Talk

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 Oct 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 Oct 2025, 18:26 UTC

Market Talk

Precious Metals Close at New Record Highs -- Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 Oct 2025, 16:03 UTC

Acquisitions, Mergers, Takeovers

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 Oct 2025, 15:35 UTC

Market Talk

Precious Metals Push Record Highs Further -- Market Talk

Peer Comparison

Price change

Codexis Inc Forecast

Price Target

By TipRanks

144.4% upside

12 Months Forecast

Average 6.33 USD  144.4%

High 11 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.25 / 2.53Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

128 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat